BR112015022631A2 - formas cristalinas de inibidores de tirosina cinase e seus sais - Google Patents

formas cristalinas de inibidores de tirosina cinase e seus sais

Info

Publication number
BR112015022631A2
BR112015022631A2 BR112015022631A BR112015022631A BR112015022631A2 BR 112015022631 A2 BR112015022631 A2 BR 112015022631A2 BR 112015022631 A BR112015022631 A BR 112015022631A BR 112015022631 A BR112015022631 A BR 112015022631A BR 112015022631 A2 BR112015022631 A2 BR 112015022631A2
Authority
BR
Brazil
Prior art keywords
salts
tyrosine kinase
kinase inhibitors
crystalline forms
forms
Prior art date
Application number
BR112015022631A
Other languages
English (en)
Portuguese (pt)
Inventor
Jie-Qiang Wu Jay
Wang Ling
Original Assignee
Mundipharma International Corporation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mundipharma International Corporation Ltd filed Critical Mundipharma International Corporation Ltd
Publication of BR112015022631A2 publication Critical patent/BR112015022631A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015022631A 2013-03-15 2014-03-14 formas cristalinas de inibidores de tirosina cinase e seus sais BR112015022631A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801112P 2013-03-15 2013-03-15
PCT/US2014/027591 WO2014152663A1 (en) 2013-03-15 2014-03-14 Crystalline forms of tyrosine kinase inhibitors and their salts

Publications (1)

Publication Number Publication Date
BR112015022631A2 true BR112015022631A2 (pt) 2017-12-19

Family

ID=51529961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022631A BR112015022631A2 (pt) 2013-03-15 2014-03-14 formas cristalinas de inibidores de tirosina cinase e seus sais

Country Status (23)

Country Link
US (5) US8999992B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970148A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016513704A (cg-RX-API-DMAC7.html)
KR (1) KR20150142688A (cg-RX-API-DMAC7.html)
CN (1) CN105377821A (cg-RX-API-DMAC7.html)
AU (1) AU2014239254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022631A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904403A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002593A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150560A (cg-RX-API-DMAC7.html)
EA (1) EA201591684A1 (cg-RX-API-DMAC7.html)
GT (1) GT201500292A (cg-RX-API-DMAC7.html)
HK (1) HK1220193A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012403A (cg-RX-API-DMAC7.html)
NI (1) NI201500139A (cg-RX-API-DMAC7.html)
PE (1) PE20151884A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015502110A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201507516XA (cg-RX-API-DMAC7.html)
SV (1) SV2015005074A (cg-RX-API-DMAC7.html)
TN (1) TN2015000407A1 (cg-RX-API-DMAC7.html)
UA (1) UA116466C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014152663A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507154B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US8999992B2 (en) * 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
JP2017529356A (ja) * 2014-09-17 2017-10-05 ムンディファーマ インターナショナル コーポレイション リミテッド チロシンキナーゼ阻害剤及びその塩の結晶形態
US20180370926A1 (en) * 2015-08-07 2018-12-27 Purdue Pharma L.P. Process of preparing tyrosine kinase inhibitor
MD3697789T2 (ro) 2017-10-18 2022-02-28 Incyte Corp Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU2065438C1 (ru) 1993-12-22 1996-08-20 Институт химии природного органического сырья СО РАН Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US6476032B2 (en) 1998-12-17 2002-11-05 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
IL146474A0 (en) 1999-06-03 2002-07-25 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
ATE343575T1 (de) 2001-09-27 2006-11-15 Smithkline Beecham Corp Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
KR20030095729A (ko) 2002-06-14 2003-12-24 크리스탈지노믹스(주) 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
WO2005020897A2 (en) 2003-08-22 2005-03-10 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
WO2008021463A2 (en) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
MXPA06011463A (es) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
FR2881138B1 (fr) 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
JP5191155B2 (ja) 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2007303392A (ja) 2006-05-11 2007-11-22 Honda Motor Co Ltd 気体燃料内燃機関の制御装置
WO2008053863A1 (en) 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
WO2008082887A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
WO2009024989A2 (en) 2007-08-17 2009-02-26 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
WO2009067197A2 (en) 2007-11-16 2009-05-28 Rayspan Corporation Filter design methods and filters based on metamaterial structures
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
EP2585466A1 (en) 2010-06-23 2013-05-01 OSI Pharmaceuticals, LLC Polymorphs of osi-906
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9376406B2 (en) 2011-03-03 2016-06-28 Indiana University Research And Technology Corporation uPAR-uPA interaction inhibitors and methods for treating cancer
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
JP2017529356A (ja) 2014-09-17 2017-10-05 ムンディファーマ インターナショナル コーポレイション リミテッド チロシンキナーゼ阻害剤及びその塩の結晶形態

Also Published As

Publication number Publication date
US20150174124A1 (en) 2015-06-25
WO2014152663A1 (en) 2014-09-25
SG11201507516XA (en) 2015-10-29
UA116466C2 (uk) 2018-03-26
MX2015012403A (es) 2016-04-04
US9388146B2 (en) 2016-07-12
US20170001969A9 (en) 2017-01-05
US20140275113A1 (en) 2014-09-18
CL2015002593A1 (es) 2016-08-19
US9993473B2 (en) 2018-06-12
US10124002B2 (en) 2018-11-13
EA201591684A1 (ru) 2016-02-29
JP2016513704A (ja) 2016-05-16
GT201500292A (es) 2019-07-29
US8999992B2 (en) 2015-04-07
PE20151884A1 (es) 2016-01-08
PH12015502110A1 (en) 2016-01-11
CR20150560A (es) 2016-08-31
US20170105990A1 (en) 2017-04-20
US9718794B2 (en) 2017-08-01
US20160002182A1 (en) 2016-01-07
EP2970148A1 (en) 2016-01-20
ZA201507154B (en) 2017-09-27
SG10201707484UA (en) 2017-10-30
AU2014239254B2 (en) 2018-06-28
US20180057469A1 (en) 2018-03-01
TN2015000407A1 (en) 2017-01-03
SV2015005074A (es) 2017-07-19
CA2904403A1 (en) 2014-09-25
NI201500139A (es) 2016-02-16
KR20150142688A (ko) 2015-12-22
EP2970148A4 (en) 2016-10-12
AU2014239254A1 (en) 2015-10-15
HK1220193A1 (zh) 2017-04-28
CN105377821A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
BR112015022631A2 (pt) formas cristalinas de inibidores de tirosina cinase e seus sais
FR24C1030I2 (fr) Sels de chlorhydrate de n-(cyanométhyl)-4-(2-(4-morpholinophénylamino)pyrimidin-4-yl)benzamide
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201792355A1 (ru) Способ получения противоракового средства 1-((4-(4-фтор-2-метил-1h-индол-5-илокси)-6-метоксихинолин-7-илокси)метил)циклопропанамина, его кристаллической формы и солей
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112015019627A2 (pt) amidas heterocíclicas como inibidores de quinases
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DK3054936T5 (da) 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
MX382171B (es) Inhibidores de replicacion del virus de influenza.
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
MX2017003439A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales.
BR112017015116A2 (pt) derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto
BR112016009665A8 (pt) polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos
BR112016002724A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica e uso de composto
BR112015005560A2 (pt) derivados de macrolídeos, sua preparação e seu uso terapêutico
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
BR112017012965A2 (pt) derivados de fumagilol
WO2015102019A3 (en) Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride
IN2014CH00732A (cg-RX-API-DMAC7.html)
BR112017007011A2 (pt) compostos de metil-piperidina úteis para inibir a prostaglandina e2 sintase-1 microssômica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 2020-01-07